ConductScience.org, home

Paper4415565

Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.

Brady RO and 4 others. N Engl J Med, 1974. Cited by 235 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. Papers, record 4415565. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4415565

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.
PubMed
Journal
N Engl J Med
PubMed
Year
1974
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
235
iCite
Relative citation ratio, by iCite
5.97
iCite
Revised in PubMed
2013-11-21
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Brady ROR O
2Pentchev PGP G
3Gal AEA E
4Hibbert SRS R
5Dekaban ASA S

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Gaucher DiseaseMajor topic
GlucosidasesMajor topic
Adolescent
Biopsy
Cerebrosides
Chromatography, Thin Layer
Erythrocytes
Female
Glucose
Glycolipids
Humans
Injections, Intravenous
Lipid Metabolism
Lipids
Liver
Male
Middle Aged
Placenta

Source PubMed

Download CSV of topics

Cited by55

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 235 citations.

PMIDTitleJournalYearIn PapersSource
39177874Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond.BioDrugs2024https://conductscience.org/library/papers/39177874PubMed
35706761Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases.GEN Biotechnol2022https://conductscience.org/library/papers/35706761PubMed
32070051Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment.Int J Mol Sci2020https://conductscience.org/library/papers/32070051PubMed
31836861Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.Nat Rev Drug Discov2020https://conductscience.org/library/papers/31836861PubMed
30128966Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.Clin Pharmacokinet2019https://conductscience.org/library/papers/30128966PubMed
30103348Centronuclear myopathies under attack: A plethora of therapeutic targets.J Neuromuscul Dis2018https://conductscience.org/library/papers/30103348PubMed
29848835Enzyme replacement therapy in India: Lessons and insights.J Postgrad Med2018https://conductscience.org/library/papers/29848835PubMed
29670214Restoring functional neurofibromin by protein transduction.Sci Rep2018https://conductscience.org/library/papers/29670214PubMed
28502768Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.Adv Drug Deliv Rev2017https://conductscience.org/library/papers/28502768PubMed
28314976Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).J Inherit Metab Dis2017https://conductscience.org/library/papers/28314976PubMed
28207759Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes.PLoS One2017https://conductscience.org/library/papers/28207759PubMed
27916601Gaucher disease: Progress and ongoing challenges.Mol Genet Metab2017https://conductscience.org/library/papers/27916601PubMed
27790078Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy.Core Evid2016https://conductscience.org/library/papers/27790078PubMed
27384562Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders.Int J Mol Sci2016https://conductscience.org/library/papers/27384562PubMed
27098312Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.Expert Rev Proteomics2016https://conductscience.org/library/papers/27098312PubMed
26471939Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group.BMC Neurol2015https://conductscience.org/library/papers/26471939PubMed
26260077Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.Mol Genet Metab2015https://conductscience.org/library/papers/26260077PubMed
24534703The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.J Lipid Res2014https://conductscience.org/library/papers/24534703PubMed
24531622Glucocerebrosidase is shaking up the synucleinopathies.Brain2014https://conductscience.org/library/papers/24531622PubMed
23554863Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage.PLoS One2013https://conductscience.org/library/papers/23554863PubMed

See all 55 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4415565

GET https://conductscience.org/api/papers/v1/4415565/cited_by?page=2